Fuji Pharma Co., Ltd.

Fuji Pharma Co., Ltd.

10.20
EUR
-0.30
(-2.86%)
0.64EPS
Feb 11Next Earn

Important Dates

Fuji Pharma Co., Ltd.'s next confirmed earnings release is scheduled for February 11, 2027.

Earnings Date2/11/2027

Share Statistics

As of June 30, 2026, Fuji Pharma Co., Ltd. has 26.12M shares outstanding.

Shares Outstanding26.12M

Financial Position

As of June 30, 2026, Fuji Pharma Co., Ltd. maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.69, indicating elevated leverage, while an interest coverage ratio of 18.47 demonstrates strong ability to service its debt obligations.

Current Ratio1.66
Quick Ratio0.30
Debt / Equity55.69
Debt / EBITDA4.12
Interest Coverage18.47

Financial Efficiency

EUR

Over the twelve months ended June 30, 2026, Fuji Pharma Co., Ltd. posted a return on equity (ROE) of 6.14, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.72 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.12, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.21, useful for judging operating efficiency across full business cycles. The company generates approximately 183,874.91 in revenue per employee across its workforce of 1,760.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.56 indicates how many times Fuji Pharma Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)6.14
Return on Assets (ROA)3.12
Return on Invested Capital (ROIC)7.72
Return on Capital Employed (ROCE)4.21
Revenue Per Employee183,874.91
Employee Count1,760.00
Inventory Turnover1.56

Taxes

EUR

Over the twelve months ended June 30, 2026, Fuji Pharma Co., Ltd. recorded 2.27M in income tax expense. That works out to an effective tax rate of 12.37, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 18.37M, leaving 16.10M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax2.27M
Effective Tax Rate12.37

Income Statement

EUR

Over the twelve months ended June 30, 2026, Fuji Pharma Co., Ltd. generated 323.62M in revenue and converted that into 16.10M in net income, yielding earnings per share of 0.64. EBITDA reached 37.78M, while operating income came in at 37.80M.

Revenue323.62M
Gross Profit127.49M
Operating Income37.80M
Pretax Income18.37M
Net Income16.10M
EBITDA37.78M
EBIT37.78M
Earnings Per Share (EPS)0.64

Balance Sheet

EUR

As of June 30, 2026, Fuji Pharma Co., Ltd. holds 53.58M in cash and equivalents against 155.57M in total debt, resulting in a net debt position of 79.01M. Total book value stands at 279.33M, with working capital of 116.95M providing operational flexibility.

Cash & Cash Equivalents53.58M
Total Debt155.57M
Net Debt79.01M
Equity (Book Value)279.33M
Book Value Per Share10.69
Working Capital116.95M

Margins

Over the twelve months ended June 30, 2026, Fuji Pharma Co., Ltd. posted a gross margin of 39.39, reflecting its pricing power and cost economics. The operating margin of 11.68 and net profit margin of 4.97 provide insight into operational efficiency.

Gross Margin39.39
Operating Margin11.68
Pretax Margin5.68
Profit Margin4.97
EBITDA Margin11.67

Stock Splits

Fuji Pharma Co., Ltd.'s most recent stock split took place on June 27, 2018 with a 1:2 split ratio.

Last Split Date6/27/2018
Split Ratio1:2